Aprea Therapeutics, Inc. Common stock
$0.75
$0.02 (+2.67%)
$0.73Day Range$0.77
Key Statistics
Market Cap
$9.44M
Shares Outstanding
12.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 3, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$0.75
Day High
$0.77
Day Low
$0.73
Volume
117.5K
VWAP
$0.74
Prev Close
$0.73
Transactions
--
Acc. Volume
--
About Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
PHARMACEUTICAL PREPARATIONSSIC 28348 employees3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902215-948-4119IPO Oct 3, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001781983
- Composite FIGI
- BBG00Q6Q3K37
- Share Class FIGI
- BBG00Q6Q3KV6
- Ticker Root
- APRE
- SIC Code
- 2834
About Aprea Therapeutics, Inc. Common stock (APRE) Stock
Aprea Therapeutics, Inc. Common stock (APRE) closed the 2026-09-17 session at $0.75, up 2.67% versus the previous close (+0.02). The stock opened at $0.75 and traded between $0.73 and $0.77 during that session. Session trading volume was 118K shares. The volume-weighted average price (VWAP) is $0.74.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Aprea Therapeutics, Inc. Common stock has a market capitalization of $9.4 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. APRE is listed on the XNAS exchange. The company employs approximately 8 people. Aprea Therapeutics, Inc. Common stock is headquartered in DOYLESTOWN, PA. The recorded listing date is 2019-10-03.
On this page you can find market APRE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.